Headlines about STAAR Surgical (NASDAQ:STAA) have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 45.7173691571307 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern’s scoring:

Shares of STAAR Surgical (NASDAQ STAA) traded up 0.46% during trading on Friday, reaching $10.90. The company had a trading volume of 40,687 shares. STAAR Surgical has a 12-month low of $7.45 and a 12-month high of $12.35. The firm has a 50-day moving average of $11.51 and a 200-day moving average of $10.28. The company’s market cap is $448.08 million.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.04. The company had revenue of $21.90 million during the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) earnings per share. On average, equities research analysts anticipate that STAAR Surgical will post ($0.11) EPS for the current year.

Several research firms have recently commented on STAA. BidaskClub raised STAAR Surgical from a “strong sell” rating to a “sell” rating in a report on Friday, August 11th. Canaccord Genuity reaffirmed a “hold” rating on shares of STAAR Surgical in a report on Tuesday, July 11th. Zacks Investment Research raised STAAR Surgical from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Saturday. Benchmark Co. upped their target price on STAAR Surgical from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, August 14th. Finally, TheStreet raised STAAR Surgical from a “d+” rating to a “c” rating in a report on Tuesday, August 15th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $12.00.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/24/staar-surgical-staa-receives-media-impact-rating-of-0-16.html.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Insider Buying and Selling by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.